Please provide your email address to receive an email when new articles are posted on . Neoadjuvant combination immunotherapy regimens produced higher pathologic response rates than monotherapy in a ...

– Zanzalintinib in combination with atezolizumab demonstrated a statistically significant reduction in risk of death versus regorafenib in intent-to-treat population – ALAMEDA, Calif., June 22, 2025-- ...